文献リスト

1) Chaudhuri KR, Healy DG, Schapira AHV, et al. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006; 5: 235-45

2) Jost WH. Autonomic dysfunction in idiopathic Parkinson's disease. J Neurol. 2003; 250 Suppl 1: I28-30

3) Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001; 57: 456-62

4) Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand. 2001; 104: 312-5

5) 服部孝道, 安田耕作, 山西友典, 他. 神経疾患による排尿障害ハンドブック. 東京: 三輪書店; 1998

6) de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol. 2006; 147 Suppl 2: S25-40

7) Kavia RBC, Dasgupta R, Fowler CJ. Functional imaging and the central control of the bladder. J Comp Neurol. 2005; 493: 27-32

8) Sakakibara R, Nakazawa K, Uchiyama T, et al. Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats. Auton Neurosci. 2002; 102: 30-8

9) Kitta T, Kakizaki H, Furuno T, et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. J Urol. 2006; 175: 994-8

10) Yamamoto T, Sakakibara R, Hashimoto K, et al. Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience. 2005; 135: 299-303

11) Yoshimura N, Kuno S, Chancellor MB, et al. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol. 2003; 139: 1425-32

12) Sakakibara R, Nakazawa K, Uchiyama T, et al. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience. 2003; 120: 871-5

13) Sakakibara R, Shinotoh H, Uchiyama T, et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci. 2001; 187: 55-9

14) Seif C, Herzog J, van der HC, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004; 55: 118-20

15) Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry. 2000; 68: 429-33

16) Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci. 2001; 92: 76-85

17) Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006; 21: 737-45

18) Sakakibara R, Hattori T, Uchiyama T, et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001; 71: 600-6

19) Yamamoto T, Sakakibara R, Uchiyama T, et al. Neurological diseases that cause detrusor hyperactivity with impaired contractile function. Neurourol Urodyn. 2006; 25: 356-60

20) Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993; 12: 203-9

21) Kuno S, Mizuta E, Yamasaki S, et al. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients. Parkinsonism Related Disord. 2004; 10: 181-7

22) Ishizuka O, Mizusawa H, Nishizawa O. Roles of dopaminergic receptors in bladder and erectile function at the spinal level. Asian J Androl. 2002; 4: 287-90

23) Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005; 27: 144-53

24) Kellow JE, Delvaux M, Azpiroz F, et al. Principles of applied neurogastroenterology: physiology/ motility-sensation. Gut. 1999; 45: 17-24

25) Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol Res. 2003; 52: 1-30

26) Anlauf M, Schafer MKH, Eiden L, et al. Chemical coding of the human gastrointestinal nervous system: cholinergic, VIPergic, and catecholaminergic phenotypes. J Comp Neurol. 2003; 459: 90-111

27) Li ZS, Schmauss C, Cuenca A, et al. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci. 2006; 26: 2798-807

28) Vaughan CJ, Aherne AM, Lane E, et al. Identification and regional distribution of the dopamine D1A receptor in the gastrointestinal tract. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R599-609

29) Banach T, Zurowski D, Gil K, et al. Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson's disease. J Physiol Pharmacol. 2006; 57: 291-300

30) Wakabayashi K, Takahachi H, Ohama E, et al. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 1990; 79: 581-3

31) Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003; 2: 107-16

32) 横山照夫, 長谷川一子. Parkinson病とイレウス. 神経内科. 2007; 66: 6-11

33) Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci. 2006; 248: 255-8

34) Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003; 74: 268-72

35) Edwards LL, Quigley EMM, Harned RK, et al. Defecatory function in Parkinson's disease; response to apomorphine. Ann Neurol. 1993; 33: 490-3

36) Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord. 2001; 16: 1176-7

37) Sakakibara R, Yamaguchi T, Uchiyama T, et al. Calcium polycarbophil improves constipation in primary autonomic failure and multiple system atrophy subjects. Mov Disord. 2007; 22: 1672-3

38) Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol. 2004; 251 Suppl 7: 18-23

39) Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord. 1995; 10: 66-70

40) Shimada J, Sakakibara R, Uchiyama T, et al. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a case of parkinsonian patient with chronic constipation. Eur J Neurol. 2006; 13: 306-12

41) Langdon N, Malcolm PN, Parkes JD. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease. Clin Neuropharmacol. 1986; 9: 440-7

42) Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord. 2005; 20: 680-6

43) Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005; 22: 997-1003

44) Madden CJ, Sved AF. Rostral ventrolateral medulla C1 neurons and cardiovascular regulation. Cell Mol Neurobiol. 2003; 23: 739-49

45) Finberg JP, Gross A, Bar-Am O, et al. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat. Br J Pharmacol. 2006; 149: 647-56

46) Lahlou S, Demenge P. Increase in the hypotensive effect of bromocriptine induced by spinal transection in rats: contribution of spinal dopamine receptors. J Cardiovasc Pharmacol. 1992; 19: 723-31

47) Stemper B, Beric A, Welsch G, et al. Deep brain stimulation improves orthostatic regulation of patients with Parkinson's disease. Neurology. 2006; 67: 1781-5

48) Magerkurth C, SchnitzerR, Braune S. Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life. Clin Auton Res. 2005; 15: 76-82

49) Orimo S, Ozawa E, Nakade S, et al. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67: 189-94

50) Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci. 2006; 243: 101-4

51) Onodera H, Okabe S, Kikuchi Y, et al. Impaired chemosensitivity and perception of dyspnoea in Parkinson's disease. Lancet. 2000; 356: 739-40

52) 新美由紀. Parkinson病の起立性低血圧. 神経内科. 2007; 66: 30-7

53) Mathias CJ, Young TM. Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. Eur J Neurol. 2004; 11: 613-9

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp